Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

v3.24.1.u1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2024
Subsequent Events  
SUBSEQUENT EVENTS

NOTE 8 — SUBSEQUENT EVENTS

 

On April 8, 2024, the Company’s appeal to BSI in connection with a prior audit matter was upheld resulting in no disruption of sales of the Company to the market and patients. Our products remain certified, marketed and sold in the EU. The Company intends to address the identified nonconformance through the routine BSI assessment process.